Last reviewed 2026-04-23 · How we verify

Intranasal Diclofenac Sodium

Intranasal diclofenac sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain.

Intranasal diclofenac sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain. Used for Acute pain management (likely indication based on intranasal NSAID development).

At a glance

Mechanism of action

Diclofenac blocks both COX-1 and COX-2 enzymes, which are responsible for producing prostaglandins that mediate inflammation, pain, and fever. The intranasal formulation delivers the drug directly to nasal mucosa for rapid systemic absorption, potentially providing faster onset of analgesia compared to oral formulations. This route of administration may also reduce gastrointestinal exposure and associated side effects.

Approved indications

• Acute pain management (likely indication based on intranasal NSAID development)

Common side effects

• Nasal irritation
• Headache
• Gastrointestinal discomfort
• Dizziness

Key clinical trials

• Intra-nasal Ketorolac for Acute Ureteral Stent-associated Pain Following Ureteroscopy for Stone Disease (PHASE1, PHASE2)
• Analgesic Effects of Intranasal Diclofenac Sodium, Ibuprofen, and Paracetamol in Pediatric Tonsillectomy Cases (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Intranasal Diclofenac Sodium CI brief — competitive landscape report
• Intranasal Diclofenac Sodium updates RSS · CI watch RSS
• Bezmialem Vakif University portfolio CI